Thirona, AI for medical image analysis firm, has closed its latest financing round with proceeds allocated to accelerating the company’s growth.
Founded in 2014, Thirona develops AI solutions for both lung and retinal image analysis. Apart from focusing on common diseases such as asthma and diabetic retinopathy, Thirona is also tackling rare and complex conditions, such as cystic fibrosis.
“We believe that science should be used for the benefit of all people. Our vision is to speed up scientific progress in healthcare by bringing together the best of science and technology. This to enable breakthroughs in treatment development and clinical care,” said Eva van Rikxoort, founder and CEO of Thirona.
Thirona translates AI-based technology into value-adding solutions and services for clinical user – from clinical trials to clinics – through partnerships and integrations. With its flagship product, LungQ, Thirona has built partnerships with pharmaceutical companies, helping to advance treatment development in clinical trials, as well as supporting pulmonary clinical care across the globe.
The company said now that it is closing in on 10 million images analysed and its solutions have been validated in over 180 scientific publications, it is looking to expand its operations and scale up its development efforts.
Guido Geerts, co-CEO of Thirona, added: “As a company, we have always placed a high emphasis on research and development which has enabled us to establish strong academic, clinical and industrial partnerships. Now, we find ourselves at a tipping point in our journey, expediting our international expansion and development goals.”
This latest funding round was led by Belgian investment fund Heran Partners and Borski Fund from the Netherlands.
“By tapping into the large market of non-oncologic lung diseases and through unparalleled innovation and high scalability of the platform, Thirona is poised to further strengthen its position as category leader in the market of image analysis. We at Heran Partners are committed to supporting Thirona’s growth plans and provide them with capital, network, and expertise in global commercialisation”, said Katleen Vandersmissen, managing partner at Heran Partners.
